<div class="white-sheet">
	<div class="content-slide">
		
		<!-- Secondary scene 1 -->
		<div class="content secondary-scene">

		<div class="title-bar red"></div>

		<div class="wrapper slide-2-8-1-1">

			<div class="vertical-nav">
                <ul style="top:570px">
                    <li class="active"></li>
                    <li></li>
                </ul>
            </div>


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Treatment of aplastic anaemia in Europe – <br />EBMT guidelines
			</div>


			<div class="content-container">

				<img class="center-img" src="media/images/slide_2_8_1-1/picture1.png" alt="" >

				<p class="small-print">
					BMT, bone marrow transplant; CsA, ciclosporin; FBC, full blood count; HLA, human leukocyte antigen; IST, immunosuppressive therapy; r-ATG, rabbit anti-thymocyte globulin; SAA, severe aplastic anaemia. European Group for Blood and Marrow Transplantation. The complete treatment algorithm for SAA. 2010<sup>1</sup>
				</p>

			</div>

		</div>

		<div class="information-overlay overlay">

			<header>Treatment of aplastic anaemia in Europe</header>
				
			<ul>
				<li><span>The European Group for Blood and Marrow Transplantation (EBMT)<sup>1</sup> is a pan-European scientific organisation founded to promote sharing of scientific knowledge and clinical experience in the field of haematopoietic stem cell transplantation</span>
					<ul>
						<li><span>This includes basic and clinical research, education, standardisation, quality control and accreditation for transplant procedures</span></li>
					</ul>
				</li>
				<li><span>This treatment algorithm was proposed for by the EMBT, taking into account different protocols across Europe in an effort to standardise practices</span></li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>European Group for Blood and Marrow Transplantation. The complete treatment algorithm for SAA. 2010. http://www.ebmt.org/Contents/Resources/Library/Slidebank/EBMT2010SlideBank/Documents/EBMT%202010%20Session%20slides/SAA_complete_treat_algorithm_v1.pdf (accessed December 2013)</span></li>
			</ul>

		</div>

		</div>
		<!-- End of secondary scene 1 -->
		    <!-- Secondary scene 2 (Static Content) -->
    <div class="content secondary-scene">
         

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-8-1a">

                    <div class="vertical-nav">
                        <ul style="top:570px">
                            <li></li>
                            <li class="active"></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>        
                    </div>

                    <div class="slide-title blue two-line">
                        Treatment of aplastic anaemia: development of the<br /> UK guidelines
                    </div>


                    
                
      					<div class="content-container" style="overflow-y:scroll;-webkit-overflow-scrolling: touch;">

      						<ul>
      							<li><span>The guideline group was selected to be representative of UK-based medical experts and experienced district general hospital haematologists, and also included a patient representative</span></li>
      							<li><span>The guideline was reviewed and approved by 59 practising UK haematologists, the British Committee for Standards in Haematology and the Committee of the British Society for Haematology</span></li>
      						</ul>
                
      					<table class="blue">

                            <tr class="odd">
                                <th>Classification of evidence levels</th>
                                <th>Source</th>
                                <th>Classification of grades of recommendation</th>
                                <th>Requirement</th>

                            </tr>


                            <tr>
                                <td>Ia</td>
                                <td>Meta-analysis of randomised controlled trials</td>
                                <td>A</td>
                                <td>At least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing specific recommendation</td>
                            </tr>


                            <tr class="odd">
                                <td>
                                	Ib
                                </td>
                                <td>At least one randomized controlled trial</td>
                                <td>A</td>
                                <td></td>
                            </tr>


                            <tr>
                                <td>
                                	IIa
                                </td>
                                <td>At least one well-designed controlled study without randomisation</td>
                                <td>B</td>
                                <td>The availability of well-conducted clinical studies but no randomised clinical trials on the topic of recommendation</td>
                            </tr>


                            <tr class="odd">
                                <td>
                                	IIb
                                </td>
                                <td>At least one other type of well-designed quasi-experimental study</td>
                                <td>B</td>
                                <td></td>
                            </tr>

                            
                            <tr>
                                <td>
                                	III
                                </td>
                                <td>Well-designed non-experimental descriptive studies, such as comparative studies, correlated studies and case studies</td>
                                <td>B</td>
                                <td></td>
                            </tr>


                            <tr class="odd">
                                <td>
                                	IV
                                </td>
                                <td>Expert committee reports or opinions and/or clinical experience of respected authorities</td>
                                <td>C</td>
                                <td>Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality</td>
                            </tr>
                        </table>                         

                    </div>                          

                </div>



                <div class="references2-overlay overlay">

                    <header>References</header>
                        
                    <ul>
                        <li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p17-27.pdf"><span>Marsh JCW <i>et al. Br J Haematol</i> 2009;147:43</span></li>
                    </ul>

                </div>

          
    </div>
    <!-- End of secondary scene 2 -->

	</div>
</div>